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By combining the mammalian two-hybrid system MAPPIT and saturation mutagenesis, we complement and extend crystallographic and NMR data, and
reveal how TIR domains interact. Our approach fully delineates the interaction sites on the MyD88 TIR domain for homo-oligomerization and for interaction
with Mal and TLR4. Interactions between three sites drive MyD88 homo-oligomerization. The BB-loop interacts with the E-helix, explaining how BB-loop
mimetics inhibit MyD88 signaling. The C’-helix interacts symmetrically. The MyD88 TIR domains thus assemble into a left-handed helix, compatible with the
Myddosome death domain crystal structure. Our assembly explains regulation of MyD88 by Mal, phosphorylation, and oncogenic mutations. These findings
provide a paradigm for the interaction of mammalian TIR domains.
Random mutagenesis and MAPPIT NF-κB activation
Adapted from Bovijn et al. (2012)
Hexameric MyD88 TIR assembly
MAPPIT is based on the JAK-STAT signaling pathway of class I cytokine receptors. Upon ligand
binding, the leptin receptor complex is reorganized, leading to recruitment and cross-activation
of associated Janus kinases (JAKs). The bait protein is fused to the mutated intracellular part of
the leptin receptor, which is deficient for the recruitment of Signal Transducer and Activator of
Transcription 3 (STAT3). The prey protein is tethered to a fragment of the gp130 receptor chain
which harbours several STAT3 recruitment sites. Upon binding of prey and bait, STAT3 is
phosphorylated and forms an activated STAT3 complex. This complex migrates to the nucleus,
resulting in the induction of a STAT3-responsive reporter gene.
(a) The first binding site “I” (BS I) includes the residues of the BB-loop. Mutations at these
positions strongly affect the interaction with MAL, MyD88 and TLR4. (b) A second binding site “II”
(BS II) is found around the C-terminal half of the αC’-helix. Mutations at the center of this binding
site affect the MyD88 TIR-MyD88 dimerization assay. (c) The third binding site “III” (BS III) is
situated at the N-terminal half of the αE-helix. Similarly to BS I, mutations at this site strongly
affect all testes interaction assays. A fourth site “IV” (BS IV) consists mostly of residues of the
DE-loop and EE-loop. Mutations in this site more specifically affect the interaction with MAL and
TLR4ic. Non-mutated residues are uncolored, and the backbone is indicated in black.
(a, b, and c) Mutations in BS I, BS III, and in the center of BS II strongly reduce the
NF-κB activation, corroborating the effect of these mutations on MyD88-MyD88
interaction. (c) Mutations in BS IV have no appreciable effect on the NF-κB reporter
activation, in line with a specific role of this site in MyD88-MAL interaction. Non-
mutated residues are uncolored, and the backbone is indicated in black.
(a) The left-handed helical MyD88 TIR model (top)
closely resembles the organization of the MyD88 death
domains in the Myddosome crystal structure (bottom).
(b) Alternating site I-III and site II-II interactions lead to
the helical MyD88 TIR model. A large Mal-specific
binding site is exposed, containing BS IV and residues
S209 and L211.
Molecular dynamics
S244D and L252P mutations affect the dynamics and position of the αC’-helix
in MyD88 TIR, which may enhance interactions via BS II. Molecular dynamics
simulations are performed on the S244D (cyan) and L252P (yellow) MyD88 TIR
mutants, and on the MyD88 TIR wild-type (black). The αC’-helix is located in
the front.
BS IV Mutations in MyD88 Disrupt Mal-Binding in a Co-Immunoprecipitation Assay.
(a) We co-transfected FLAG-tagged wild-type or mutant MyD88 with E-tagged Mal. FLAG-tagged SVT was transfected as a
negative control. All mutations in BS IV, indicated by *, abolish the interaction with Mal (all p-values < 0.01), while the S244A
and S244D mutations do not disrupt MAL-binding. The L252P mutation (p < 0.0001) also abolishes binding with MAL, but this
could be due to lower expression of the mutant. (b) Densitometric analysis of the effect of MyD88 mutants on MAL-binding.
Data are represented as relative area from three up to five independent experiments.
MyD88-Mal Co-IP
